Introduction Central airway nitric oxide flux (J' awNO ) and peripheral airway/alveolar nitric oxide concentration (C ANO ) during asthma exacerbation has not been investigated after correction for axial NO back-diffusion. Methods After measuring exhaled NO (fraction of exhaled nitric oxide (F E NO); ppb) at 50, 100, 150 and 200 ml/s, J' awNO (nl/s) and C ANO (ppb) were calculated using the two-compartment model and corrected for axial NO back-diffusion. Fifteen (8 males), non-smoking, patients with moderate-to-severe treated (inhaled corticosteroid (ICS) and inhaled long-acting b 2 -agonist (LABA)) asthma, age 57613 years (mean6SD), were studied at baseline, during exacerbation prior to oral corticosteroid, and during recovery after an 8 day tapering prednisone course. Based on earlier asthma studies without correction, it was hypothesised that with correction for NO axial back-diffusion, the incidence of abnormal J' awNO and C ANO at baseline and after exacerbation would be $30% in 15 patients with asthma with 80% power.Results At baseline when clinically stable, after 180 mg of albuterol, forced expiratory volume in 1 s (FEV 1 ; litres) was 78626% predicted (p¼0.009) with increased F E NO at 50 ml/s (p¼0.01) and J' awNO (p¼0.02), but C ANO was normal compared with the controls. During exacerbation FEV 1 (litres) was 57620% predicted (p¼0.02), with increased F E NO at 50 ml/s (p¼0.01) and J' awNO (p¼0.004), but C ANO was normal. Recovery results were similar to baseline. Two of 15 patients with asthma always had normal exhaled NO gas exchange. Conclusions The central airways were the major site of abnormal NO flux in 13 of 15 patients with moderateesevere asthma when stable and during exacerbation and could be easily detected with abnormal F E NO at 50 ml/s. C ANO was normal. Clinical trial number NCT00576069.Measurement of the fraction of exhaled nitric oxide (F E NO; ppb) is a relatively simple, reproducible and non-invasive test for monitoring airway inflammation.1 Increased F E NO in asthma is accepted as a surrogate for predominantly eosinophilic-mediated inflammation in central airways and increased response to inhaled corticosteroid (ICS).1e5 The currently accepted method of measuring F E NO at a single constant expiratory flow rate, usually 50 ml/s, is incapable of separating out whether the source of increased NO production is the large central airways or the peripheral small airway/ alveolar site, or both. clinically stable asthma. However, two groups independently 12 22 have also demonstrated, both experimentally and theoretically, axial back-diffusion of NO from proximal to peripheral airway/ alveoli, against the direction of exhalation. Furthermore, this may contaminate peripheral airway/alveolar levels, leading to an underestimation of central airway NO flux and an overestimation of peripheral airway/alveolar NO levels. Axial NO back-diffusion has not been previously accounted for in those with asthma with abnormal expiratory airflow limitation.The current prospective outpatient study eva...